Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Innovage Holding Corp. (INNV)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
$9.09-7.15%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.50 → 0.52 EPS · FY ending Jun 30, 2028 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for INNV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA reaches at least $85 million in fiscal 2026 | Adjusted EBITDA guidance was raised to $90 million, showing better operations. | Intact | Adjusted EBITDA falls below $85 million in fiscal 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented healthcare business with improving recent financial performance, but it is not yet a proven durable compounder because it remains loss-making. The multi-year view is intact, though the recent earnings miss and leadership transition make execution worth watching.
Valuation is tagged as stretched, with the model showing INNV at about peer-level valuation and expectations somewhat ahead of the baseline view. The market appears to credit recent growth and improving adjusted EBITDA, while the evidence gives little sign of a large cushion if results disappoint.
In the near term, revenue and adjusted EBITDA have grown, and management has raised guidance for both; those priorities are on track. However, the company remains loss-making, recent earnings have been erratic with consecutive misses, and the new COO’s impact is not yet measurable.
The near-term case depends on management maintaining or raising guidance rather than cutting it. Over the multi-year view, continued execution and supportive healthcare-sector results would help, while weakening job growth and recession fears could pressure cyclical healthcare businesses.
INNV’s 1-to-3-year thesis rests on sustaining strong revenue growth and improving adjusted EBITDA while addressing its loss-making profile. The setup remains intact, but elevated risk and stretched expectations make execution the key test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company hired a new President and COO to improve leadership. |
| Intact |
| Key executive roles remain unfilled or unstable past mid-2026 |
Leadership transition complete (Jennifer Browne appointed May 2026) Jennifer Browne appointed President and COO in May 2026. No subsequent news indicates leadership instability or vacancies. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “In her role, Ms. Browne will oversee InnovAge’s market operations and core support functions, with a focus on driving consistent execution, enhancing the participant experience, and advancing the Company’s performance across its key operational and compliance metrics.” “Ms. Browne’s appointment reflects InnovAge’s continued focus on disciplined execution, regulatory excellence, and sustainable growth as the Company advances its mission to help older adults live independently for as long as possible.” Delivery assessment Nov 5, 2026 |
Fiscal 2026 revenue reaches at least $925 million | A primary condition in Innovage Holding Corp.'s published investment case. The stated target is >= $925 million. | Intact | Fiscal 2026 revenue falls below $925 million | Revenue: $264.757M FY2027-Q1; GAAP. Published target: >= $925 million. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 2026264,757,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.47 → $0.52 · observed estimates
$1.12B → $1.16B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-25 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-26 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-27 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-28 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-29 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-30 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-07-31 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-01 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-02 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-03 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-04 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-05 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-06 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-07 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-08 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-09 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-10 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-12 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-13 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-14 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-15 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-16 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-17 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-18 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-19 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-20 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-21 | $0.47 | $1,118,664,567 | 2 / 2 |
| 2026-08-22 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-23 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-24 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-25 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-26 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-27 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-28 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-29 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-30 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-08-31 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-01 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-02 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-03 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-04 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-05 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-06 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-07 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-08 | $0.49 | $1,118,664,567 | 2 / 2 |
| 2026-09-09 | $0.57 | $1,169,200,000 | 1 / 2 |
| 2026-09-10 | $0.49 | $1,162,100,000 | 2 / 2 |
| 2026-09-11 | $0.49 | $1,162,100,000 | 2 / 2 |
| 2026-09-12 | $0.49 | $1,162,100,000 | 2 / 3 |
| 2026-09-13 | $0.49 | $1,162,100,000 | 2 / 3 |
| 2026-09-14 | $0.49 | $1,162,100,000 | 2 / 3 |
| 2026-09-15 | $0.49 | $1,162,100,000 | 2 / 3 |
| 2026-09-16 | $0.49 | $1,162,100,000 | 2 / 3 |
| 2026-09-17 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-18 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-19 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-20 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-21 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-22 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-23 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-24 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-25 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-26 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-27 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-28 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-29 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-09-30 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-01 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-02 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-03 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-04 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-05 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-06 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-07 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-08 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-09 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-10 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-11 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-12 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-13 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-14 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-15 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-16 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-17 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-18 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-19 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-20 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-21 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-22 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-23 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-24 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-25 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-26 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-27 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-28 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-29 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-30 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-10-31 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-11-01 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-11-02 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-11-03 | $0.50 | $1,159,733,333 | 2 / 3 |
| 2026-11-04 | $0.52 | $1,163,266,667 | 2 / 3 |
| 2026-11-05 | $0.52 | $1,163,266,667 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.